Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIBRATO: Ritlecitinib and Brepocitinib in Ulcerative Colitis
NCT02958865Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2017
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of ritlecitinib tosilate and brepocitinib in ulcerative colitis (UC) (10 arms), sponsored by Pfizer. Primary endpoint: Total Mayo Score at 8 weeks. Started Feb 2017; status: completed.
02
Drugs
ritlecitinib tosilatebrepocitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02958865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958865.